326

  • Web Address
  • DOI
  • Date of creation in the UzSCI system02-05-2020
  • Read count297
  • Date of publication06-10-2019
  • Main LanguageRus
  • Pages298-303
Tags
№ Name of reference
1 1. Mohd Hanafiah K., Groeger J., Flaxman A. D., Wiersma S. T./ Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence // Hepatology. ‒ Place Published, 2013. ‒ T. 57, № 4. ‒ C. 1333-42. 2. Norah A Terrault /Challenges in HCV Elimination // JAMA. ‒ Place Published, 2017. ‒ T. 318, № 10. ‒ C. 899. 3. Inoue T., Tsuzuki Y., Iio E., Shinkai N., Matsunami K., Fujiwara K., Matsuura K., Nojiri S., Tanaka Y. /Clinical Evaluation of Hepatocarcinogenesis and Outcome Using a Novel Glycobiomarker Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFA(+)-M2BP) in Chronic Hepatitis C with Advanced Fibrosis // Jpn J. Infect Dis. ‒ Place Published,2018. ‒ T. 71, № 3. ‒ C. 177-183. 4. Kuno A., Ikehara Y., Tanaka Y., Ito K., Matsuda A., Sekiya S., Hige S., Sakamoto M., Kage M., Mizokami M., Narimatsu H. /A serum "sweet- doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis // Sci Rep. ‒ Place Published, 2013. ‒ T. 3. ‒ C. 1065. 5. Kuno A, Ikehara Y, Tanaka Y,et al. /Aserum―sweet- doughnut‖proteinfacilitatesfibrosis evaluation andtherapy assessment in patients withviralhepatitis.Sci Rep2013;3: 1065 6. Artini M., Natoli C., TinariN. et al. /Elevated serum levels of 90K/MAC- 2BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients //J Hepatol 1996; 25: 212–7. 7. Kuno A., Sato T., Shimazaki H. et all. /Reconstruction of a robustglyco diagnostic agent supported bymultiple lectin-assisted glycan profiling// Proteomics Clin Appl 2013;7: 642–7
Waiting